CivaDerm(TM) Surface Therapy Pilot Study

Launched by CIVATECH ONCOLOGY · Jul 20, 2020

Keywords

ClinConnect Summary

The CivaDerm(TM) Surface Therapy Pilot Study is looking at a new treatment for patients with certain types of skin cancer, specifically basal cell carcinoma and squamous cell carcinoma. This study is testing a special device that delivers targeted radiation therapy to the surface of the skin. The goal is to see if this new approach can effectively treat tumors while minimizing side effects.

To participate in this study, you should be between 65 and 74 years old and have a confirmed diagnosis of superficial or nodular basal or squamous cell carcinoma located on your chest, stomach, back, arms, legs, or feet. Your tumor should be larger than 5 mm but smaller than 3 cm, and you must be able to follow the study instructions. If you are pregnant, breastfeeding, or have cancer that has spread to other parts of your body, you won't be able to join. If eligible, you can expect to receive the new treatment and be monitored throughout the study. This is an important step in finding better options for skin cancer treatment, and your participation could help improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • subject signed informed consent
• • Confirmed superficial or nodular basal cell or squamous cell carcinoma
• • Biopsy proven on chest, stomach, back, arms, legs, feet (trunk and extremities)
• • \>5 mm of residual tumor
• • tumors \< 3 cm
• • Capable of complying with Patient Release Instructions
• Exclusion Criteria:
• • Is unable or unwilling to comply with the protocol requirements
• • Pregnant or breast feeding
• • Metastases